Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide for prevention of blood-stained CSF and neurological dysfunction in thoracoabdominal aortic surgery
2013-001447-31Phase 3Terminated
- Sponsor
- Liverpool Heart and Chest Hospital
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of acetazolamide in intracranial hypertension (IH), Thoracoabdominal aortic aneurysm (TAAA) and Thoracoabdominal aortic disease (TAAD) (2 arms), sponsored by Liverpool Heart and Chest Hospital. Primary endpoint: Incidence of blood-stained cerebrospinal fluid during drainage. Started Oct 2013; status: terminated.
02
Drugs
acetazolamide
03
Conditions
intracranial hypertension (IH)Thoracoabdominal aortic aneurysm (TAAA)Thoracoabdominal aortic disease (TAAD)
Beyond the preview
Go deeper on 2013-001447-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001447-31.